STOCK TITAN
  1. Home
  2. News
  3. OCS

Oculis Holding AG Ordinary shares - OCS STOCK NEWS

Welcome to our dedicated page for Oculis Holding Ordinary shares news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding Ordinary shares stock.

Oculis Holding AG (Nasdaq: OCS) is a leading global biopharmaceutical company dedicated to saving sight and enhancing eye care. Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is at the forefront of developing innovative treatments for serious eye diseases. The company's pipeline includes several promising candidates:

  • OCS-01: A topical eye drop for diabetic macular edema (DME) and post-cataract surgery inflammation and pain. OCS-01 has shown compelling Phase 3 data, making it a potential new standard of care for these conditions.
  • OCS-02: A topical biologic anti-TNFα eye drop for dry eye disease (DED) and non-infectious anterior uveitis. The OCS-02 RELIEF trial is in Phase 2b, with results eagerly anticipated.
  • OCS-05: A neuroprotective candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders such as glaucoma and diabetic retinopathy. The ACUITY trial is set to provide critical data by the end of the year.

Oculis recently announced its fourth-quarter and full-year 2023 financial results, highlighted by positive Phase 3 data for OCS-01 and the commencement of three clinical trials, including OCS-02's RELIEF trial. The company is on track for a catalyst-rich 2024 with significant upcoming milestones, including readouts from the RELIEF trial in Q2 and the OPTIMIZE-2 and ACUITY trials in Q4. These milestones are crucial for Oculis' plan to submit its first New Drug Application (NDA).

Under the leadership of CEO Riad Sherif, M.D., Oculis has achieved remarkable progress and continues to advance its diversified pipeline. The company is backed by leading international healthcare investors and boasts a seasoned management team with a strong track record of success.

Financially, Oculis has reported significant strides, supported by both new and existing investors. The company has dual listings on Nasdaq in the U.S. and Iceland, reflecting its robust financial health and market confidence.

For more information, please visit Oculis Holding AG's website. For investor and media inquiries, contact Ms. Sylvia Cheung, CFO at sylvia.cheung@oculis.com or Corey Davis, Ph.D. at LifeSci Advisors at cdavis@lifesciadvisors.com.

News

Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNFα Licaminlimab (OCS-02) in Dry Eye Disease

Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announces the initiation of the Phase 2b RELIEF trial to evaluate the potential of licaminlimab (also known as OCS-02), a novel anti-TNFα biologic eye drop, for the treatment of Dry Eye Disease (DED). The trial aims to assess the efficacy and safety of licaminlimab in moderate-to-severe DED, with topline results expected in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
clinical trial
-
News

Oculis Reports Q3 2023 Financial Results and Provides Company Update

Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) reported that its lead product candidate OCS-01 eye drop met primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain after cataract surgery, following a positive readout of Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME). The company also enrolled the first patient in the investigator-initiated LEOPARD trial evaluating OCS-01 for the treatment of cystoid macular edema (CME). Oculis has cash and investments of $116.5 million, which is adequately funded to deliver on key business and clinical milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
earnings
-
News

Oculis to Present at Upcoming November Investor Conferences

Rhea-AI Summary
Oculis Holding AG (Nasdaq: OCS) announced that its CEO and CFO will be presenting at upcoming investor conferences, including the Stifel 2023 Healthcare Conference and BTIG 3rd Annual Ophthalmology Day. The management team will also attend the Piper Sandler 35th Annual Healthcare Conference, offering one-on-one meetings for interested investors. Links to access company presentation and webcast for select events will be posted to Oculis’ website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
conferences
News

Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema

Rhea-AI Summary
Oculis Holding AG announced positive results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 in patients with diabetic macular edema (DME). The results will be presented at the American Academy of Ophthalmology (AAO) 2023 Annual Meeting. OCS-01 is the first investigational eye drop for both front and back of the eye indications, with positive results in previous trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
conferences clinical trial
-
News

Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress

Rhea-AI Summary
Oculis announces positive results from Phase 3 DIAMOND trial for DME
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
clinical trial
-
News

Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema

Rhea-AI Summary
Oculis Holding AG announces positive readout from Phase 3 DIAMOND trial of OCS-01 in patients with DME
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
conferences clinical trial
News

Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase

Rhea-AI Summary
Oculis appoints Rebecca Weil as Chief Commercial Officer following positive clinical milestones on OCS-01 and NASDAQ listing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
management
-
News

Oculis to Present at Upcoming September Investor Conferences

Rhea-AI Summary
Oculis Holding AG to present at upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences
-
News

Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update

Rhea-AI Summary
Oculis achieved positive Phase 3 results for OCS-01 in diabetic macular edema and inflammation and pain following cataract surgery. Raised $146 million in gross proceeds. Enrolled first patient in LEOPARD trial for cystoid macular edema.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
earnings
News

OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery

Rhea-AI Summary
Oculis Holding AG has announced positive top line results from its Phase 3 OPTIMIZE trial with OCS-01 eye drops. The trial demonstrated superior reduction in inflammation and pain compared to the vehicle following cataract surgery. OCS-01 has the potential to become the first once-daily, topical, preservative-free corticosteroid for treating inflammation and pain following ocular surgery.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
clinical trial

FAQ

What is the current stock price of Oculis Holding Ordinary shares (OCS)?

The current stock price of Oculis Holding Ordinary shares (OCS) is $17.56 as of January 3, 2025.

What is the market cap of Oculis Holding Ordinary shares (OCS)?

The market cap of Oculis Holding Ordinary shares (OCS) is approximately 734.2M.

What is Oculis Holding AG?

Oculis Holding AG is a global biopharmaceutical company focused on developing treatments for serious eye diseases, including diabetic macular edema and dry eye disease.

What products are in Oculis' pipeline?

Oculis' pipeline includes OCS-01 for diabetic macular edema, OCS-02 for dry eye disease, and OCS-05 for acute optic neuritis and other neuro-ophthalmic disorders.

Where is Oculis headquartered?

Oculis is headquartered in Switzerland, with additional operations in the U.S. and Iceland.

What recent achievements has Oculis made?

In 2023, Oculis had positive Phase 3 results for OCS-01 and initiated three clinical trials, including the OCS-02 Phase 2b RELIEF trial for dry eye disease.

Who leads Oculis Holding AG?

Oculis is led by CEO Riad Sherif, M.D., alongside an experienced management team with a successful track record and support from leading international healthcare investors.

What are the upcoming milestones for Oculis in 2024?

Upcoming milestones include the RELIEF trial readout for OCS-02 in Q2, and Phase 3 readouts for OCS-01 and OCS-05 in Q4, along with the submission of the first NDA.

How did Oculis perform financially in 2023?

Oculis reported strong financial results for 2023, supported by significant investor backing and a successful dual listing on Nasdaq in the U.S. and Iceland.

What conditions does OCS-01 treat?

OCS-01 is a topical eye drop candidate for treating diabetic macular edema (DME) and for post-cataract surgery inflammation and pain.

What is the OCS-02 RELIEF trial?

The OCS-02 RELIEF trial is a Phase 2b clinical study evaluating the efficacy of OCS-02, a topical biologic anti-TNFα eye drop, for treating dry eye disease (DED).

How can I contact Oculis for investor or media inquiries?

For inquiries, you can contact CFO Sylvia Cheung at sylvia.cheung@oculis.com or Corey Davis, Ph.D., at cdavis@lifesciadvisors.com.
Stock OCS logo
Oculis Holding AG Ordinary shares

Nasdaq:OCS

OCS Rankings

#2791 Ranked by Market Cap
N/A Ranked by Dividends

OCS Stock Data

734.25M
38.93M
7.23%
32.2%
0.06%
Biotechnology
Healthcare
Link
United States of America
Zug